Adamis Pharmaceuticals Corporation: Drug Recall
Recall #D-0764-2022 · 03/21/2022
Class I: Dangerous
Recall Details
- Recall Number
- D-0764-2022
- Classification
- Class I
- Product Type
- Drug
- Recalling Firm
- Adamis Pharmaceuticals Corporation
- Status
- Terminated
- Date Initiated
- 03/21/2022
- Location
- San Diego, CA, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,500 cartons
Reason for Recall
Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
Product Description
SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.
Distribution Pattern
Nationwide in the U.S.A.
Other Recalls by Adamis Pharmaceuticals Corporation
- Class I: Dangerous 03/21/2022
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.